/
Oncology
Advanced or Metastatic Solid Tumour
6
Pipeline Programs↗
5
Active Trials↗
11
Companies Involved↗
Advanced or Metastatic Solid Tumour is an early-stage landscape with 6 programs across 11 companies. The most active players are Shijiazhuang Yiling Pharmaceutical Co. Ltd, Elpiscience (Suzhou) Biopharma, Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 14
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
3 of 4 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.
Analysis
Trial Status
13
clinical trials
Completed6 · 46%
Recruiting3 · 23%
Active, not recruiting1 · 8%
Unknown status1 · 8%
Terminated1 · 8%
Not yet recruiting1 · 8%
Clinical Trials
Trial Activity
13 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)